<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02929251</url>
  </required_header>
  <id_info>
    <org_study_id>P150945 2016-002284-34</org_study_id>
    <nct_id>NCT02929251</nct_id>
  </id_info>
  <brief_title>Randomized Trial Comparing Efficacy of Adalimumab, Anakinra and Tocilizumab in Non-infectious Refractory Uveitis</brief_title>
  <acronym>RUBI</acronym>
  <official_title>Multicentre, Randomized, Multi-arm Trial Comparing the Efficacy and Safety of Adalimumab, Anakinra and Tocilizumab in Subjects With Non-infectious Refractory Uveitis RUBI: Refractory Uveitis BIotherapies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      RUBI, is the first prospective randomized, head to head study, comparing Adalimumab to either&#xD;
      anakinra, or tocilizumab in refractory Non Infectious Uveitis (NIU). There is no firm&#xD;
      evidence or randomized controlled trials directly addressing the best biologic agent in&#xD;
      severe and refractory NIU. NIU can cause devastating visual loss and up to 20% of legal&#xD;
      blindness. Corticosteroids and immunosuppressants failed to demonstrate sustainable remission&#xD;
      over 70 % of refractory/relapsing severe uveitis. The incidence of blindness in NIU has been&#xD;
      dramatically reduced in the recent years with the use of biologics, raising the question of&#xD;
      whether these compounds should be used earlier in the treatment of severe non infectious&#xD;
      uveitis. Contrasting with immunosuppressors, biotherapies act rapidly and are highly&#xD;
      effective in steroid's sparing thus preventing occurrence of cataract and/or glaucoma.&#xD;
&#xD;
      Despite a strong rationale, these compounds are not yet approved in uveitis, which guarantees&#xD;
      the innovative nature of this study that aims selecting or dropping any arm when evidence of&#xD;
      efficacy already exists.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">June 28, 2017</start_date>
  <completion_date type="Anticipated">May 2019</completion_date>
  <primary_completion_date type="Anticipated">May 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of patients with at least 2-step reduction in Vitreous Haze (according to Miami 9-step Scale) and with a dose &lt;= 0.1 mg/Kg/day of prednisone (or equivalent oral corticosteroid)</measure>
    <time_frame>Week 16</time_frame>
    <description>Percentage of patients with at least 2-step reduction in Vitreous Haze (according to Miami 9-step Scale) and with a dose &lt;= 0.1 mg/Kg/day of prednisone (or equivalent oral corticosteroid)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline in Vitreous Haze</measure>
    <time_frame>Week 4, 8, 12, 16, 24</time_frame>
    <description>Mean change from baseline in Vitreous Haze</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with anterior chamber score = 0 or at least 2-step reduction in score (Tyndall and flare according to the Standardization of Uveitis Nomenclature (SUN) classification)</measure>
    <time_frame>Week 4, 8, 12, 16, 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline in BCVA (ETDRS letters score)</measure>
    <time_frame>Week 4, 8, 12, 16, 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline in central retinal thickness measured with Optical Coherence Tomography (OCT)</measure>
    <time_frame>Week 4, 8, 12, 16, 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with Central Retinal Thickness (CRT) &lt;300 microns</measure>
    <time_frame>Week 4, 8, 12, 16, 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients without retinal vessel leakage on fluorescein angiography</measure>
    <time_frame>Week 4, 8, 12, 16, 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent meeting targets ≤ 0.1 mg/day prednisone</measure>
    <time_frame>week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change in prednisone dose</measure>
    <time_frame>Week 4, 8, 12, 16, 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean dose of prednisone</measure>
    <time_frame>week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative dose of prednisone</measure>
    <time_frame>week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to response onset</measure>
    <time_frame>week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to relapse of uveitis</measure>
    <time_frame>week 30</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of relapse of uveitis</measure>
    <time_frame>week 30</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Underlying systemic disease</measure>
    <time_frame>week 4, 8, 12, 16, 24</time_frame>
    <description>Complete remission of extra opthalmologic sign of Behcet disease or sarcoidosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of adverse event</measure>
    <time_frame>week 4, 8, 12, 16, 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of serious adverse event</measure>
    <time_frame>week 4, 8, 12, 16, 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time to treatment failure</measure>
    <time_frame>week 30</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Uveitis</condition>
  <condition>Biotherapy</condition>
  <arm_group>
    <arm_group_label>Adalimumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Adalimumab (40mg/14 days subcutaneously) (n=40) for 16 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Anakinra</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Anakinra (100 mg/day subcutaneously) (n=40) for 16 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tocilizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tocilizumab (162 mg/7 days subcutaneously) (n=40) for 16 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anakinra</intervention_name>
    <description>Anakinra (100 mg/day subcutaneously) (n=40) for 16 weeks</description>
    <arm_group_label>Anakinra</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tocilizumab</intervention_name>
    <description>Tocilizumab (162 mg/7 days subcutaneously) (n=40) for 16 weeks.</description>
    <arm_group_label>Tocilizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adalimumab</intervention_name>
    <description>Adalimumab (40mg/14 days subcutaneously) (n=40) for 16 weeks</description>
    <arm_group_label>Adalimumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Provide written, informed consent prior to the performance of any study specific&#xD;
             procedures&#xD;
&#xD;
          2. Diagnosis of non-infectious intermediate, posterior-, or pan-uveitis in at least one&#xD;
             eye fulfilling the International Study Group Classification Criteria (Standardization&#xD;
             of Uveitis Nomenclature [SUN] criteria) of posterior, or pan- uveitis confirmed by&#xD;
             documented medical history&#xD;
&#xD;
          3. Currently uncontrolled uveitic disease. Uncontrolled uveitic disease is defined as&#xD;
             fulfilling of the two following criteria at Inclusion:&#xD;
&#xD;
               -  Active inflammatory chorioretinal and/or inflammatory retinal vascular lesions OR&#xD;
&#xD;
               -  Vitreous haze grade &gt;1+ according to the SUN National Eye Institute (NEI) Scoring&#xD;
                  for Vitreous Haze&#xD;
&#xD;
          4. Are receiving prednisone ≥10 mg/day (or equivalent dose of another corticosteroid) and&#xD;
             at least 1 other systemic immunosuppressant, or,&#xD;
&#xD;
               -  . Are receiving IFNalpha or,&#xD;
&#xD;
               -  To be intolerant to immunosuppressant&#xD;
&#xD;
          5. Best corrected visual acuity (BCVA) by ETDRS of 20/20 to 20/400 (approximately 85 to&#xD;
             20 letters) in the study eye&#xD;
&#xD;
          6. Best corrected visual acuity (BCVA) by ETDRS of 20/20 or better in the fellow eye&#xD;
             (approximately 20 letters)&#xD;
&#xD;
          7. Stable dose for two weeks prior to inclusion of topical corticosteroids and/or NSAIDs&#xD;
&#xD;
          8. Male or female , Age &gt;= 18 years at Inclusion&#xD;
&#xD;
          9. Weight 40 - 120 kg (88.2 - 264 lbs) at Inclusion&#xD;
&#xD;
         10. Chest X-ray results (postero-anterior and lateral) within 12 weeks prior to Inclusion&#xD;
             with no evidence of active Tuberculosis, active infection, or malignancy&#xD;
&#xD;
         11. For female subjects of child-bearing age, a negative serum pregnancy test&#xD;
&#xD;
         12. For subjects with reproductive potential, a willingness to use contraceptive measures&#xD;
             adequate to prevent the subject or the subject's partner from becoming pregnant during&#xD;
             the study. Adequate contraceptive measures include hormonal methods used for two or&#xD;
             more cycles prior to Screening (e.g., oral contraceptive pills, contraceptive patch,&#xD;
             or contraceptive vaginal ring), barrier methods (e.g., contraceptive sponge, diaphragm&#xD;
             used in conjunction with contraceptive foam or jelly, or condom used in conjunction&#xD;
             with contraceptive foam or jelly), intrauterine methods (IUD), sterilization (e.g.,&#xD;
             tubal ligation or a monogamous relationship with a vasectomized partner), and&#xD;
             abstinence.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Infectious uveitis, masquerade syndromes, or uveitis due to causes other than non&#xD;
             infectious uveitis disease (idiopathic uveitis is permitted)&#xD;
&#xD;
          2. Isolated anterior uveitis&#xD;
&#xD;
          3. Presence of cataract or posterior capsular opacification so severe that an assessment&#xD;
             of the posterior segment of either eye is inadequate or impossible&#xD;
&#xD;
          4. Contraindication to mydriasis in either eye or presence of posterior synechiae in the&#xD;
             study eye such that mydriasis is inadequate for posterior segment examination&#xD;
&#xD;
          5. Intraocular pressure ≥ 25 mmHg by Goldmann tonometry or advanced glaucoma (e.g.,&#xD;
             cup-to-disc ratio &gt; 0.9, split fixation on visual field, or need for &gt; 3 intraocular&#xD;
             pressure lowering medications to keep Intra Ocular Pressure (IOP) &lt; 22 mmHg) in either&#xD;
             eye&#xD;
&#xD;
          6. Monocular patient&#xD;
&#xD;
          7. Active tuberculosis or history of untreated tuberculosis&#xD;
&#xD;
          8. Known positive syphilis serology, HIV antibody, hepatitis B surface antigen or&#xD;
             anti-nucleocapsid antibody of hepatitis B virus, and/or hepatitis C antibody.&#xD;
&#xD;
          9. History of malignancy within 5 years prior to Inclusion other than carcinoma in situ&#xD;
             of the cervix or adequately treated, non-metastatic squamous or basal cell carcinoma&#xD;
             of the skin.&#xD;
&#xD;
         10. History of severe allergic or anaphylactic reactions to monoclonal antibodies&#xD;
&#xD;
         11. Infectious disease:&#xD;
&#xD;
               -  Fever or infection requiring treatment with antibiotics within 3 weeks prior to&#xD;
                  Inclusion&#xD;
&#xD;
               -  History of recurrent infection or predisposition to infection&#xD;
&#xD;
         12. Known immunodeficiency&#xD;
&#xD;
         13. History of multiple sclerosis and/or demyelinating disorder&#xD;
&#xD;
         14. Laboratory values assessed during Inclusion:&#xD;
&#xD;
               -  Hemoglobin &lt; 8g/dL&#xD;
&#xD;
               -  White Blood Cell Count (WBC) &lt; 2.0 x 103/mm3&#xD;
&#xD;
               -  Platelet count &lt; 80 x 103/mm3&#xD;
&#xD;
               -  Glomerular filtration rates (GFR) &lt;30ml/min.&#xD;
&#xD;
               -  Transaminases &gt; 3 times upper normal value&#xD;
&#xD;
         15. Use of the following systemic treatments during the specified periods:&#xD;
&#xD;
               -  Any other previous systemic biologic therapy&#xD;
&#xD;
               -  Any prior treatment with tocilizumab, anakinra, or anti Tumor Necrosis Factor&#xD;
                  (TNF)&#xD;
&#xD;
               -  Treatment with any systemic alkylating agents within 12 months prior to Inclusion&#xD;
                  or between Inclusion and Day 0 (e.g., cyclophosphamide, chlorambucil)&#xD;
&#xD;
               -  Any live (attenuated) vaccine within 3 months prior to Inclusion; recombinant or&#xD;
                  killed virus vaccines are permitted. Live seasonal flu and H1N1 vaccines are&#xD;
                  permitted ≥ 2 weeks prior to Inclusion.&#xD;
&#xD;
         16. Use of the following ocular treatments during the specified periods:&#xD;
&#xD;
               -  Previous anti Vascular Endothelial Growth Factor (VEGF) intravitreal therapy&#xD;
                  within 3 months prior to Inclusion, or anticipated use during the study period&#xD;
&#xD;
               -  Treatment with dexamethasone intravitreal implant [Ozurdex®]) within 6 months&#xD;
                  prior to Inclusion&#xD;
&#xD;
               -  Intravitreal corticosteroids within 3 months prior to Inclusion. Previous&#xD;
                  Subtenon's corticosteroid injections are permitted if administered at least 2&#xD;
                  months prior to Inclusion&#xD;
&#xD;
         17. Stage III and IV New York Heart Association (NYHA) cardiac insufficiency&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Saadoun, MD PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>APHP</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>David Saadoun, MD PHD</last_name>
    <phone>142178009</phone>
    <phone_ext>+33</phone_ext>
    <email>david.saadoun@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>matthieu Resche-Rigon, MD PHD</last_name>
    <phone>142499742</phone>
    <phone_ext>+33</phone_ext>
    <email>matthieu.resche-rigon@univ-paris-diderot.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hopital La Pitié Salpetriere</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>david saadoun, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <study_first_submitted>October 7, 2016</study_first_submitted>
  <study_first_submitted_qc>October 10, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 11, 2016</study_first_posted>
  <last_update_submitted>December 7, 2017</last_update_submitted>
  <last_update_submitted_qc>December 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uveitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adalimumab</mesh_term>
    <mesh_term>Interleukin 1 Receptor Antagonist Protein</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

